AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31353126
Drug: Vocal Facilitating
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal Facilitating Techniques (VFTs); 10 individual sessions, twice a week
Trial: 31353126
Drug: Manual Circumlaryngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Circumlaryngeal Therapy (MCT); 10 individual sessions, twice a week
Trial: 28796913
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g foam
Trial: 28796913
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g gel
Trial: 28796913
Drug: Cal/BD foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD foam and gel vs. latest topical treatment (LTT)
Trial: 27531752
Drug: Cal/BD gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD gel
Trial: 25731215
Drug: Insulin needle
RxNorm normalized name: BD Regular Insulin Needle 19gx1"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin needle
Trial: 19028932
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid supplements
Trial: 14759453
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (heparin plus nafamostat, 0.2 mg/kg bolus followed by 2.0 mg/kg/h during cardiopulmonary bypass)
Trial: 14759453
Drug: Aprotinin (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (heparin plus aprotinin, 2.0 x 10(4) KIU/kg)
Trial: 11060418
Drug: Nadroparin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (low molecular weight heparin)
Trial: 3549083
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (cyclophosphamide, dipyridamole, and warfarin)
Trial: 3549083
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among patients with IgA nephritis (n = 27)
Trial: 3549083
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) among patients with IgA nephritis (n = 21)
Trial: 3549083
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among matched pairs (n = 23)
Trial: 3549083
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) among matched pairs (n = 23)
Trial: 30945105
Drug: Dexmedetomidine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (30 µg)
Trial: 22699827
Drug: Overground therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overground therapy
Trial: 17586139
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of mifepristone once every 14 days for six cycles
Trial: 15680804
Drug: Early low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early low-dose steroid therapy (methylprednisolone, 2 mg/kg loading dose followed by 2 mg/kg per day)
Trial: 10605950
Drug: Low-dose wine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose wine group
Trial: 10605950
Drug: High-dose wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose wine group
Trial: 2228846
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination (SDD) with initial systemic cefotaxime (500 mg tid for 5 days)
Trial: 2228846
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group A (antibiotics that disturb colonization resistance)
Trial: 2228846
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group B (antibiotics not affecting colonization resistance)
Trial: 356244
Drug: Voltaren (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voltaren (diclofenac sodium) 50 mg
Trial: 23644549
Drug: golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 50 mg every 4 weeks
Trial: 25387477
Drug: golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 100 mg after dose adjustment
Trial: 12233104
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment in group A (sick sinus syndrome with pacemaker)
Trial: 12233104
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment in group B (atrial fibrillation without pacemaker)
Trial: 12233104
Drug: Warfarin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosage in group A
Trial: 12233104
Drug: Warfarin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosage in group B
Trial: 7590502
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g fish oil
Trial: 7590502
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g corn oil (placebo)
Trial: 2138595
Drug: naloxone 0.4
RxNorm normalized name: NALOXONE 0.4MG/0.4ML AUTOINJECTOR,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 0.4 mg (i.m.)
Trial: 2138595
Drug: naloxone 4
RxNorm normalized name: naloxone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 4 mg (i.v.)
Trial: 2138595
Drug: naloxone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (both doses)
Trial: 6766833
Drug: Phenobarbital 60
RxNorm normalized name: phenobarbital 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 60 mg orally
Trial: 6766833
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid 250 mg orally twice daily for 14 days + Phenobarbital 60 mg orally on day 4
Trial: 31332998
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy for 6 months
Trial: 23306584
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (approximately 3 ml/kg) combined with extracorporeal CO2 elimination
Trial: 23306584
Drug: ARDSNet strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARDSNet strategy (approximately 6 ml/kg) without the extracorporeal device
Trial: 22009805
Drug: Atracourium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracourium (5 mg in 0.5 ml)
Trial: 22009805
Drug: cis-Atracourium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-Atracourium (5 mg in 0.5 ml)
Trial: 22009805
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 ml normal saline)
Trial: 20467603
Drug: 5-mm-long Rescue
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mm-long Rescue implants (Megagen)
Trial: 20467603
Drug: 10-mm-long implants
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mm-long implants placed in augmented bone
Trial: 20467603
Drug: Augmented group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented group (10-mm-long implants)
Trial: 7709928
Drug: Osteoporosis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoporosis therapy (specific intervention details not provided)
Trial: 2311147
Drug: Propofol (2.0‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.0‐2.5 mg.kg‐1 followed by a continuous infusion 0.1‐0.2 mg.kg‐1.min‐1)
Trial: 2311147
Drug: Thiopentone (4.0‐5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4.0‐5.0 mg.kg‐1, infusion rate 0.16‐0.32 mg.kg‐1.min‐1)
Trial: 6107500
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus levamisole 2.5 mg/kg/day for two consecutive days each week for 48 weeks
Trial: 22032120
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray (64 microg per, 256 microg once daily)
Trial: 22032120
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal spray (twice daily)
Trial: 20069203
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg per day)
Trial: 20069203
Drug: Nortriptyline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (20 mg per day)
Trial: 20069203
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Propranolol and Nortriptyline (40 mg and 20 mg per day respectively)
Trial: 15139978
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg weekly)
Trial: 11838927
Drug: Short duration
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short duration antibiotic prophylaxis (2 days)
Trial: 11838927
Drug: Long duration
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long duration antibiotic prophylaxis (7 days)
Trial: 3383994
Drug: l-carnitine 20
RxNorm normalized name: L-Carnitine 200mg/1mL Solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine 20 mg/kg
Trial: 3383994
Drug: l-carnitine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine 40 mg/kg
Trial: 3383994
Drug: l-carnitine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine 60 mg/kg
Trial: 3383994
Drug: l-carnitine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine infusion
Trial: 27654729
Drug: Topical finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical finasteride 0.5%
Trial: 22904030
Drug: Extended-release memantine
RxNorm normalized name: memantine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release memantine
Trial: 17355732
Drug: Cilastatin co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilastatin co-administered with cyclosporin A
Trial: 11996956
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg initially, increased to 40 mg if necessary)
Trial: 10434236
Drug: Lornoxicam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (8 mg tid for 3 days)
Trial: 10434236
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg tid for 3 days)
Trial: 7776115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diazepam and acetaminophen
Trial: 1972011
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no beta-adrenergic agonist)
Trial: 112656
Drug: ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketotifen (1 mg twice daily)
Trial: 112656
Drug: disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: disodium cromoglycate (20 mg four times daily)
Trial: 29499082
Drug: Traditional herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional herbal medicine (THM)
Trial: 23810626
Drug: Go4it group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Go4it group treatment
Trial: 22842422
Drug: One-stage reconstruction
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage reconstruction with a round permanent expander implant (Becker 25)
Trial: 20085534
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg/day for 3 weeks, then up-titrated to OM 40 mg/day for 3 weeks, and subsequently to OM/HCTZ 40/12.5 mg/day or OM/HCTZ 40/25 mg/day as necessary
Trial: 17073853
Drug: Dexpanthenol pastille
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol pastille (200 mg, two pastilles sucked 30 min before operation)
Trial: 17073853
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride spray (four puffs, sprayed 30 min before operation and 5 min before anaesthesia induction)
Trial: 15764945
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of two single‐standing titanium screw implants with cortical satellite implants and overdentures
Trial: 8997168
Drug: IVIG-and-aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVIG-and-aspirin
Trial: 8997168
Drug: Aspirin-alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin-alone
Trial: 30824398
Drug: Resistance exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercises 2 days/week and aerobic exercises 1 day/week for 9 months with isoenergetic supplements containing 0, 10, 20, or 30 g whey protein twice daily
Trial: 29399800
Drug: Alginos Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginos Oral Suspension (sodium alginate 1,000 mg three times daily)
Trial: 29399800
Drug: Alginos Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginos Oral Suspension
Trial: 27090863
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH (300 IU daily for 7 days)
Trial: 23036134
Drug: Anticholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic therapy (solifenacin 5 mg initially, possible escalation to 10 mg, switch to trospium XR 60 mg)
Trial: 23036134
Drug: OnabotulinumtoxinA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (100 U injection)
Trial: 18294115
Drug: Anticholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic therapy
Trial: 14616431
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of dexmedetomidine (2 microg x kg-1)
Trial: 14616431
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of dexmedetomidine (2 microg x kg-1)
Trial: 14616431
Drug: Peroral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral administration of dexmedetomidine (2 microg x kg-1)
Trial: 10842420
Drug: 1.47 g
RxNorm normalized name: FERRIC OXIDE RED 2.3 g in 1 g / ZINC OXIDE 21.47 g in 1 g TOPICAL OINTMENT [DERMASEPTIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.47 g protein/kg body cell mass/d (marginal diet)
Trial: 10842420
Drug: 2.94 g
RxNorm normalized name: ZINC OXIDE 2.94 g in 28 g TOPICAL CREAM [SPF 16 BRIGHTENING]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.94 g protein/kg body cell mass/d (adequate diet)
Trial: 8737627
Drug: 0.250 mg
RxNorm normalized name: DIGOXIN 0.250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.250 mg brotizolam
Trial: 1521686
Drug: Indirect evaluation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect evaluation using M‐L scale
Trial: 28439987
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg/day
Trial: 25546001
Drug: Tafamidis 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 400 mg
Trial: 16891338
Drug: Ethyl-eicosapentanoic acid
RxNorm normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ethyl-eicosapentanoic acid (ethyl-EPA) 2 g per day
Trial: 11509461
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) self-help programme; 6 months follow-up
Trial: 9586828
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (beta-carotene 15 mg, vitamin C 150 mg, vitamin E 75 mg, selenium 101 microg, calcium 1.6 g daily)
Trial: 7922794
Drug: rectal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rectal salmon calcitonin (sCT), 100 IU daily (n = 25)
Trial: 7922794
Drug: nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal salmon calcitonin (sCT), 200 IU daily (n = 17)
Trial: 7922794
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (18 age‐matched women who received no treatment)
Trial: 3044871
Drug: Cefatrizine 75
RxNorm normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefatrizine 75 mg/kg.day once daily for 8 days
Trial: 3044871
Drug: Cefatrizine 75
RxNorm normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefatrizine 75 mg/kg.day twice daily for 8 days
Trial: 23829621
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house dust mite (HDM) extracts
Trial: 11399214
Drug: Daily maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily maintenance doses of 4 mg/70 kg (n = 14) or 8 mg/70 kg (n = 19) of liquid buprenorphine
Trial: 10962771
Drug: Triple the
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg)
Trial: 11399214
Drug: Quintuple the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quintuple the daily maintenance dose every 120 hours (20 or 40 mg/70 kg)
Trial: 11399214
Drug: Open-dosing procedures
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-dosing procedures with three dosing regimens
Trial: 8381674
Drug: 7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/day of a 85% n-3 fatty acid concentrate
Trial: 3690030
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (1.5 mg.kg-1, orally twice a day for 14 days)
Trial: 30849287
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy for 6 weeks
Trial: 30849287
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for 6 weeks
Trial: 31099218
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (abdominal acupuncture + periodic therapy of Chinese herbal medicine)
Trial: 31099218
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (clomiphene citrate + human chorionic gonadotrophin)
Trial: 25444222
Drug: Community consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community consultation and public disclosure (CC/PD) process using multimedia approach
Trial: 25444222
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of the CC/PD process
Trial: 25444222
Drug: Effectiveness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effectiveness of the CC/PD process
Trial: 22010914
Drug: Earlier ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Earlier ART (within 2 weeks after the initiation of treatment for tuberculosis)
Trial: 22010914
Drug: Later ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis)
Trial: 15080862
Drug: Subcutaneous apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous apomorphine injection